adalimumab vs golimumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Crohn's Disease
Shared mechanism: TNF-alpha · full Crohn's Disease pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00055497 · Phase 3 · completed
Design meets top-tier criteria (randomized, quadruple-blind, placebo-controlled, hard clinical endpoint), but the randomized comparison population was very small (only 55 total randomized participants across 3 arms) and the two primary analysis methods gave discordant significance results (NRI missed, LOCF met), which per the definitions caps this at moderate under both the underpowered-n and mixed/unclear-primary-result tests.
Next expected readout: June 2027 · NCT06045754 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4: Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4 (Week 4): Double-Blind Period, Weeks 0 to 4: Placebo 6.8% vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg 37.3%; p=<0.001 (Double-Blind Period, Weeks 0 to 4: Placebo vs Double-Blind Period, Weeks 0 to 4: Adalimumab 160/80 mg) (met)
Result source: NCT02499783
golimumab · Simponi
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Crohn's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | golimumab |
|---|---|---|
| Clinical remission (induction) | 37.3% vs 6.8%+30.5 vs placeboNCT024997831 other result
| —Not reported |
| Endoscopic response (induction) | —Trial running · NCT05040464 | —Not reported |
| Clinical remission (maintenance) | 47.4% vs 33.3%+14.1 vs placeboNCT0005549711 other results
| —Not reported |
| Endoscopic response (maintenance) | —Trial running · NCT05040464 | —Not reported |
Clinical remission (induction)
- adalimumab
- 37.3% vs 6.8%+30.5 vs placeboNCT02499783
1 other result
- 46.9% vs 27.7% NCT00348283
- golimumab
- —Not reported
Endoscopic response (induction)
- adalimumab
- —Trial running · NCT05040464
- golimumab
- —Not reported
Clinical remission (maintenance)
- adalimumab
- 47.4% vs 33.3%+14.1 vs placeboNCT00055497
11 other results
- 66.7% vs 33.3% NCT00055497
- 78.9% vs 44.4% NCT00055497
- 83.3% vs 44.4% NCT00055497
- 38.1% vs 9.1% NCT00445432
- 36.3% vs 38.9% NCT00055497
- 40.2% vs 38.9% NCT00055497
- 32.8% vs 9.2% NCT00348283
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- 57.9% vs 38.9% NCT00055497
- 94.4% vs 38.9% NCT00055497
- golimumab
- —Not reported
Endoscopic response (maintenance)
- adalimumab
- —Trial running · NCT05040464
- golimumab
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
golimumab: registry results are on file for Crohn's Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. adalimumab: 4 of 4 rows · golimumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab |
|---|---|
| Dropout rate | —40 mg every other weeka NCT00055497 · Phase 3 show 34 more results15.8%40 mg every other week NCT00055497 · Phase 3 11.1%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 40.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 48.5% NCT00195715 · Phase 3 16.9%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.4% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 6.8%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 6.8%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 21.4% NCT02185014 · Phase 3 · monotherapy 61% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 60%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 34.4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 35.7%80 mg NCT01958827 · Phase 3 · monotherapy 16.4%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 70.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 36% NCT02148718 · Phase 4 · registry result, not featured evidence 26.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 26.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weeka NCT00055497 · Phase 3 show 34 more results5.3%40 mg every other week NCT00055497 · Phase 3 5.6%40 mg every week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 12.7%40 mg NCT00055497 · Phase 3 —160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 15.7% NCT00195715 · Phase 3 6%40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 1.5% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 3.9%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 2.4%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy —Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 7.1% NCT02185014 · Phase 3 · monotherapy 8% NCT00686374 · Phase 3 · monotherapy —40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 —20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 21.9%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 3%160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 5.9%80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 10.7%80 mg NCT01958827 · Phase 3 · monotherapy 10.9%40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 16.4%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination — NCT02148718 · Phase 4 · registry result, not featured evidence 20%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 20%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.3%40 mg every other weeka NCT00055497 · Phase 3 show 34 more results—40 mg every other week NCT00055497 · Phase 3 —40 mg every week NCT00055497 · Phase 3 0%40 mg every week NCT00055497 · Phase 3 16.7%40 mg NCT00055497 · Phase 3 2%160/80 mg NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 38.1% NCT00195715 · Phase 3 —40 mg every other week or every week NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 14.8% NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 4.5%Induction: Higher Induction Dose NCT02065570 · Phase 3 · monotherapy 4.9%Induction: Standard Induction Dose NCT02065570 · Phase 3 · monotherapy 4.6%Maintenance: Clinically Adjusted ( NCT02065570 · Phase 3 · monotherapy 6.4%Maintenance: Therapeutic Drug Mana NCT02065570 · Phase 3 · monotherapy —Maintenance: Therapeutic Drug Moni NCT02065570 · Phase 3 · monotherapy 10.7% NCT02185014 · Phase 3 · monotherapy 48% NCT00686374 · Phase 3 · monotherapy 23.7%40 mg or 20 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20%20 mg or 10 mg every other week NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 8%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy 40.6%40 mg Eow NCT00445432 · Phase 2/3 · monotherapy —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —160 mg/80 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80/40 mg + 40/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 —80 mg/40 mg NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 28.6%80 mg NCT01958827 · Phase 3 · monotherapy —40 mg every other week NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 10.9%300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) NCT02764762 · Phase 4 · registry result, not featured evidence · combination 2.3% NCT02148718 · Phase 4 · registry result, not featured evidence —Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 7.7%Low Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence —Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 6.7%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence 14.3%Standard Induction Dose NCT02015793 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weeka nasopharyngitis 26.3% (placebo 38.9%) crohn's disease aggravated 21.1% (placebo 27.8%) sinusitis 21.1% (placebo 5.6%) NCT00055497 · Phase 3 show 28 more results40 mg every week crohn's disease aggravated 11.1% (placebo 27.8%) dizziness (excl vertigo) 11.1% (placebo 5.6%) nasopharyngitis 11.1% (placebo 38.9%) NCT00055497 · Phase 3 40 mg crohn's disease aggravated 17.6% (placebo 27.8%) nasopharyngitis 16.7% (placebo 38.9%) headache 14% (placebo 11.1%) NCT00055497 · Phase 3 160/80 mg white blood cell count decreased 5.9% (placebo 1%) cough 4.9% (placebo 0%) dizziness 3.9% (placebo 0%) NCT02499783 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg every other week or every week headache 18.9% nasopharyngitis 14.4% arthralgia 7.6% NCT00409617 · Phase 3 · monotherapy · Crohn's Disease · phase 3 crohn's disease 23.4% (placebo 29.2%) headache 14.1% (placebo 9.2%) nasopharyngitis 14.1% (placebo 12.3%) NCT00348283 · Phase 3 · monotherapy · Crohn's Disease · phase 3 viral upper respiratory tract infection 39% headache 37% upper respiratory tract infection 31% NCT00686374 · Phase 3 · monotherapy 40 mg or 20 mg every other week headache 17.2% crohn's disease 11.8% nausea 10.8% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 20 mg or 10 mg every other week headache 21.1% crohn's disease 15.8% nasopharyngitis 11.6% NCT00409682 · Phase 3 · monotherapy · Crohn's Disease · phase 3 40 mg Eow nasopharyngitis 56% (placebo 12%) rhinorrhoea 16% (placebo 0%) adverse drug reaction 12% (placebo 4%) NCT00445432 · Phase 2/3 · monotherapy 40 mg Eow nasopharyngitis 71.9% (placebo 12%) adverse drug reaction 18.8% (placebo 4%) iron deficiency anaemia 18.8% (placebo 0%) NCT00445432 · Phase 2/3 · monotherapy 160 mg/80 mg + 40/40 mg adverse drug reaction 11.1% (placebo 4.3%) application site swelling 11.1% (placebo 0%) blood creatine phosphokinase (at investigator's discretion) 11.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 160 mg/80 mg headache 9.1% (placebo 4.3%) upper respiratory tract infection 9.1% (placebo 4.3%) abdominal distension 6.1% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80/40 mg + 40/40 mg headache 16.7% (placebo 4.3%) abdominal distension 8.3% (placebo 0%) abdominal pain 8.3% (placebo 4.3%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 80 mg/40 mg injection site reaction 8.8% (placebo 8.7%) malaise 8.8% (placebo 0%) rhinorrhoea 8.8% (placebo 0%) NCT00445939 · Phase 2/3 · monotherapy · Crohn's Disease · phase 2/3 40 mg every other week crohn's disease 16.1% abdominal pain 7.6% injection site reaction 7.6% NCT00427921 · Phase 3 · monotherapy · Crohn's Disease · phase 3 300 mg (IV) + 160-80-40 mg (SC) + 15 mg (Oral) arthralgia 18.2% crohn's disease 16.4% nasopharyngitis 10.9% NCT02764762 · Phase 4 · registry result, not featured evidence · combination vomiting 7% abdominal mass 5.8% arthralgia 4.7% NCT02148718 · Phase 4 · registry result, not featured evidence Low Induction Dose leukopenia 20% pyrexia 13.3% arthralgia 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Low Induction Dose leukopenia 15.4% animal bite 7.7% aphthous stomatitis 7.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose alanine aminotransferase increased 13.3% aspartate aminotransferase increased 13.3% abdominal pain 6.7% NCT02015793 · Phase 2 · registry result, not featured evidence Standard Induction Dose mycobacterium tuberculosis complex test positive 14.3% aspartate aminotransferase increased 7.1% asthenia 7.1% NCT02015793 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 11 more results
show 80 more results
show 11 more results
show 11 more results
show 6 more results
show 1 more result
show 4 more results
+ 62 further endpoints in the CSV export.
Ulcerative Colitis
Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00385736 · Phase 3 · completed
Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.
Next expected readout: September 2027 · NCT06257875 (registry estimate)
Reported efficacy
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)
Result source: NCT00408629
golimumab · Simponi
Marketed by Johnson & Johnson
NCT01863771 · Phase 3 · completed
Design meets the 'strong' bar: randomized, double-blind (participant and investigator masked), placebo-controlled, phase 3, with a hard clinical endpoint (Mayo score-based clinical response); the primary comparison was clearly met in the favorable direction (18/32 vs 6/31, non-overlapping 95% CIs).
Reported efficacy
Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Number of Participants Who Achieved Clinical Response Through Maintenance-Week 54 Measured Using the Mayo Score (Up to Week 54): Placebo 6/31 (19.4%) (95% CI 5.4-33.3) vs Golimumab 18/32 (56.3%) (95% CI 39.1-73.4) (met)
Result source: NCT01863771
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | golimumab |
|---|---|---|
| Clinical remission (induction) | 10% vs 11.5%−1.5 vs placeboNCT008530996 other results
| 17.9% vs 6.4%+11.5 vs placeboNCT004875391 other result
|
| Clinical remission (maintenance) | 20% vs 7.3%+12.7 vs placeboNCT0085309914 other results
| —Trial running · NCT03596645 |
| Clinical response (induction) | 50% vs 35.4%+14.6 vs placeboNCT008530994 other results
| 54.9% vs 30.3%+24.6 vs placeboNCT004875391 other result
|
| Endoscopic improvement (induction) | 44.4% vs 30.2%+14.2 vs placeboNCT008530992 other results
| —Trial running · NCT03596645 |
| Corticosteroid-free remission (maintenance) | 13.3% vs 5.7%+7.6 vs placeboNCT004086295 other results
| 23.2% vs 18.4%+4.8 vs placeboNCT004886311 other result
|
Clinical remission (induction)
- adalimumab
- 10% vs 11.5%−1.5 vs placeboNCT00853099
6 other results
- 13.8% vs 11.5% NCT00853099
- 10% vs 9.2% NCT00385736
- 18.5% vs 9.2% NCT00385736
- 16.5% vs 9.3% NCT00408629
- 10% vs 11.5% NCT00853099
- 13.8% vs 11.5% NCT00853099
- golimumab
- 17.9% vs 6.4%+11.5 vs placeboNCT00487539
1 other result
- 17.8% vs 6.4% NCT00487539
Clinical remission (maintenance)
- adalimumab
- 20% vs 7.3%+12.7 vs placeboNCT00853099
14 other results
- 26.4% vs 7.3% NCT00853099
- 17.3% vs 8.5% NCT00408629
- 29% vs 33.3% NCT02065557
- 45.2% vs 33.3% NCT02065557
- 27.3% vs 33.3% NCT02065557
- 42.9% vs 33.3% NCT02065557
- 20% vs 7.3% NCT00853099
- 17.8% vs 8.3% NCT00853099
- 26.4% vs 7.3% NCT00853099
- 17.2% vs 8.3% NCT00853099
- 42.9% vs 37.5% NCT02065557
- 45.5% vs 37.5% NCT02065557
- 42.9% vs 37.5% NCT02065557
- 44% vs 37.5% NCT02065557
- golimumab
- —Trial running · NCT03596645
Clinical response (induction)
- adalimumab
- 50% vs 35.4%+14.6 vs placeboNCT00853099
4 other results
- 42.5% vs 35.4% NCT00853099
- 54.6% vs 44.6% NCT00385736
- 51.5% vs 44.6% NCT00385736
- 50.4% vs 34.6% NCT00408629
- golimumab
- 54.9% vs 30.3%+24.6 vs placeboNCT00487539
1 other result
- 51% vs 30.3% NCT00487539
Endoscopic improvement (induction)
- adalimumab
- 44.4% vs 30.2%+14.2 vs placeboNCT00853099
2 other results
- 39.1% vs 30.2% NCT00853099
- 41.1% vs 31.7% NCT00408629
- golimumab
- —Trial running · NCT03596645
Corticosteroid-free remission (maintenance)
- adalimumab
- 13.3% vs 5.7%+7.6 vs placeboNCT00408629
5 other results
- 13.3% vs 5.7% NCT00408629
- 30.8% vs 40% NCT02065557
- 31.3% vs 40% NCT02065557
- 26.7% vs 40% NCT02065557
- 35.3% vs 40% NCT02065557
- golimumab
- 23.2% vs 18.4%+4.8 vs placeboNCT00488631
1 other result
- 28.2% vs 18.4% NCT00488631
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. adalimumab: 9 of 9 rows · golimumab: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | golimumab Rows use multiple source trials |
|---|---|---|
| Clinical Remission responder rate · % of participants No placebo or comparator arm | 100% (n=585) @ 388wk40 mg EOW/EWa,b,c NCT00573794 · Phase 3 · monotherapy | 36.6% (n=71) @ 12wkd,a,b,c NCT03662542 · Phase 2 · registry result, not featured evidence · combination show 1 more dose22.2% (n=72) @ 12wk NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Clinical Response responder rate · % of participants Maintenance | 30.2% (n=248) vs 18.3% (n=246) placebo @ 52wk160/80/40e,f,g NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 6 other source trials65.7% (n=35) vs 33.3% (n=12) placebo @ 52wkhigh dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 57.6% (n=33) vs 33.3% (n=12) placebo @ 52wkstandard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 67.7% (n=31) vs 33.3% (n=12) placebo @ 52wkhigh dose NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 61.3% (n=31) vs 33.3% (n=12) placebo @ 52wkstandard dose NCT02065557 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 31.1% (n=90) vs 17.7% (n=96) placebo @ 52wk160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 29.9% (n=87) vs 17.7% (n=96) placebo @ 52wk80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 56.3% (n=32) vs 19.4% (n=31) placebo @ 54wk*e,f,g NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 · converted to % from 18 participants as posted 2 other source trials49.7% (n=151) vs 31.2% (n=154) placebo @ 54wk*100 mg NCT00488631 · Phase 3 · combination · converted to % from 75 Participants as posted 47% (n=151) vs 31.2% (n=154) placebo @ 54wk*50 mg NCT00488631 · Phase 3 · combination · converted to % from 71 Participants as posted |
| Endoscopic Improvement event count · % of participants Induction | 46.9% (n=130) vs 41.5% (n=130) placebo @ 8wk160/80/40d,h,i,j,k NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 1 more dose37.7% (n=130) vs 41.5% (n=130) placebo @ 8wk80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 45.1% (n=257) vs 28.7% (n=251) placebo @ 6wk*400 mg -> 200 mgd,h,i,j,k NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 116 Participants as posted show 1 more dose42.3% (n=253) vs 28.7% (n=251) placebo @ 6wk*200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 · converted to % from 107 Participants as posted |
| Partial Mayo responder rate · % of participants No placebo or comparator arm | 44.1% (n=59) @ 288wk*l,b,f,m NCT02632175 · Phase 3 · monotherapy · converted to % from 26 Participants as posted | 24.9% (n=205) @ 54wkl,b,f,m NCT02092285 · Phase 4 · registry result, not featured evidence |
| Sustained Clinical Remission responder rate · % of participants | 8.5% (n=248) vs 4.1% (n=246) placebo160/80/40b,f,n NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 | 27.8% (n=151) vs 15.6% (n=154) placebo*100 mgd,b,f,n NCT00488631 · Phase 3 · combination · converted to % from 42 Participants as posted show 3 more doses38.9% (n=54) vs 24.1% (n=54) placebo*100 mg NCT00488631 · Phase 3 · combination · converted to % from 21 Participants as posted 23.2% (n=151) vs 15.6% (n=154) placebo*50 mg NCT00488631 · Phase 3 · combination · converted to % from 35 Participants as posted 36.5% (n=52) vs 24.1% (n=54) placebo*50 mg NCT00488631 · Phase 3 · combination · converted to % from 19 Participants as posted |
| Dropout rate | 6.9%160/80/40o NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results9.2%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 37.6%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 52.5% NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 10.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 56.4%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 34.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 33.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 23.8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | —100 mgp NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 28 more results—100 mg NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.6%Group1: Golimumab [Induction] NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —200 mg NCT00488631 · Phase 3 29.2%100 mg NCT00488631 · Phase 3 · combination —100 mg - 200 mg NCT00488631 · Phase 3 53.3%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg - 200 mg NCT00488631 · Phase 3 —100 mg NCT00488631 · Phase 3 44.8%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg NCT00488631 · Phase 3 27.9%50 mg NCT00488631 · Phase 3 · combination —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 1.2%400 mg -> 200 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 0.9%200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 4.2%100 mg -> 50 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 7.1%Golimumab Induction Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 4.3%Golimumab Maintenance Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 23.7% NCT02318667 · Phase 4 · registry result, not featured evidence 17.1% NCT02092285 · Phase 4 · registry result, not featured evidence 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 6.9%Combination Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Golimumab Monoth NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Discontinued due to AEs | 3.1%160/80/40o NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results4.6%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 — NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.8%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 14.3%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5.6% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | —100 mgp NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 28 more results—100 mg NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 6.3%Group1: Golimumab [Induction] NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —200 mg NCT00488631 · Phase 3 7.8%100 mg NCT00488631 · Phase 3 · combination —100 mg - 200 mg NCT00488631 · Phase 3 12.3%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg - 200 mg NCT00488631 · Phase 3 —100 mg NCT00488631 · Phase 3 13%100 mg NCT00488631 · Phase 3 · monotherapy —100 mg NCT00488631 · Phase 3 7.8%50 mg NCT00488631 · Phase 3 · combination —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg - 100 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 —50 mg NCT00488631 · Phase 3 0.3%400 mg -> 200 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 0.3%200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 2.8%100 mg -> 50 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 —Golimumab Induction Therapy NCT03124121 · Phase 4 · registry result, not featured evidence —Golimumab Maintenance Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 2.6% NCT02318667 · Phase 4 · registry result, not featured evidence 3.4% NCT02092285 · Phase 4 · registry result, not featured evidence 0%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 0%Combination Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Monotherapy Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy —Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination —Safety Follow-up: Golimumab Monoth NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Serious AEs | 4%160/80/40o NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results3.8%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 12.1%Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 27.1% NCT02632175 · Phase 3 · monotherapy 7.8%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 5.6%open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.6%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 13.9%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.2%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.8%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 5%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.6%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.8%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 9.9%Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 26.7%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 11.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 16.1%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.5% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 3.1%100 mgp NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 28 more results10%100 mg NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 3.5%Group1: Golimumab [Induction] NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.3%200 mg NCT00488631 · Phase 3 14.3%100 mg NCT00488631 · Phase 3 · combination 7.1%100 mg - 200 mg NCT00488631 · Phase 3 15.6%100 mg NCT00488631 · Phase 3 · monotherapy 0%100 mg - 200 mg NCT00488631 · Phase 3 19.4%100 mg NCT00488631 · Phase 3 14.8%100 mg NCT00488631 · Phase 3 · monotherapy 25%100 mg NCT00488631 · Phase 3 8.4%50 mg NCT00488631 · Phase 3 · combination 24%50 mg - 100 mg NCT00488631 · Phase 3 5.3%50 mg - 100 mg NCT00488631 · Phase 3 11.8%50 mg NCT00488631 · Phase 3 0%50 mg NCT00488631 · Phase 3 4.5%400 mg -> 200 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 3%200 mg -> 100 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 4.2%100 mg -> 50 mg NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 9.5%Golimumab Induction Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 0%Golimumab Maintenance Therapy NCT03124121 · Phase 4 · registry result, not featured evidence 10.5% NCT02318667 · Phase 4 · registry result, not featured evidence 23.9% NCT02092285 · Phase 4 · registry result, not featured evidence 1.4%Combination Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 1.4%Combination Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 4.2%Monotherapy Phase: Combination The NCT03662542 · Phase 2 · registry result, not featured evidence · combination 4.5%Monotherapy Phase: Golimumab Monot NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy 0%Safety Follow-up: Combination Ther NCT03662542 · Phase 2 · registry result, not featured evidence · combination 0%Safety Follow-up: Golimumab Monoth NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | 160/80/40o colitis ulcerative 4% (placebo 3.6%) fatigue 4% (placebo 2.2%) headache 3.1% (placebo 7.2%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 17 more results80/40 headache 6.9% (placebo 7.2%) colitis ulcerative 5.4% (placebo 3.6%) nasopharyngitis 4.6% (placebo 1.8%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 17.5% (placebo 10.4%) colitis ulcerative 16.3% (placebo 22.3%) headache 8.6% (placebo 14.2%) NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 33.9% upper respiratory tract infection 27.1% nasopharyngitis 22% NCT02632175 · Phase 3 · monotherapy high dose headache 9.8% (placebo 16.7%) anaemia 5.9% (placebo 8.3%) nausea 5.9% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 open-label high dose headache 22.2% (placebo 16.7%) abdominal pain 11.1% (placebo 8.3%) oropharyngeal pain 11.1% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 12.5% (placebo 16.7%) colitis ulcerative 6.3% (placebo 16.7%) nasopharyngitis 6.3% (placebo 8.3%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 high dose colitis ulcerative 11.1% (placebo 16.7%) nasopharyngitis 11.1% (placebo 8.3%) upper respiratory tract infection 11.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 18.2% (placebo 16.7%) c-reactive protein increased 9.1% (placebo 0%) colitis ulcerative 9.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 8.4% nasopharyngitis 5.1% arthralgia 3.1% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 6.1% colitis ulcerative 5.3% nasopharyngitis 4.2% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 13.4% nasopharyngitis 13.1% arthralgia 6.6% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 17.4% nasopharyngitis 13.6% arthralgia 6.7% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 15.2% nasopharyngitis 7.3% upper respiratory tract infection 6% NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 40 mg EOW/EW colitis ulcerative 30.4% viral upper respiratory tract infection 19.4% arthralgia 10.5% NCT00573794 · Phase 3 · monotherapy 160 mg/80 mg nasopharyngitis 33.3% (placebo 21.9%) iron deficiency anaemia 8.9% (placebo 7.3%) headache 7.8% (placebo 6.3%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 80 mg/40 mg nasopharyngitis 21.8% (placebo 21.9%) injection site reaction 8% (placebo 2.1%) dental caries 6.9% (placebo 5.2%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 13.2% headache 13% nasopharyngitis 8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 100 mgp nasopharyngitis 53.1% (placebo 22.6%) injection site erythema 15.6% (placebo 0%) influenza 12.5% (placebo 3.2%) NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 26 more results100 mg nasopharyngitis 23.3% (placebo 22.6%) colitis ulcerative 6.7% (placebo 6.5%) upper respiratory tract inflammation 6.7% (placebo 0%) NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 11.8% (placebo 22.6%) colitis ulcerative 4.9% (placebo 6.5%) injection site erythema 3.5% (placebo 0%) NCT01863771 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 200 mg colitis ulcerative 28.6% (placebo 18.6%) gastroenteritis viral 28.6% (placebo 0%) nasopharyngitis 28.6% (placebo 6.4%) NCT00488631 · Phase 3 100 mg nasopharyngitis 14.9% (placebo 6.4%) colitis ulcerative 11.7% (placebo 18.6%) headache 7.8% (placebo 9%) NCT00488631 · Phase 3 · combination 100 mg - 200 mg nasopharyngitis 21.4% (placebo 6.4%) headache 14.3% (placebo 9%) viral upper respiratory tract infection 14.3% (placebo 0%) NCT00488631 · Phase 3 100 mg colitis ulcerative 12.1% (placebo 18.6%) nasopharyngitis 8.1% (placebo 6.4%) arthralgia 7.2% (placebo 7.1%) NCT00488631 · Phase 3 · monotherapy 100 mg - 200 mg colitis ulcerative 30% (placebo 18.6%) diarrhoea 20% (placebo 4.5%) gastroenteritis 20% (placebo 1.9%) NCT00488631 · Phase 3 100 mg colitis ulcerative 23.7% (placebo 18.6%) nasopharyngitis 16.4% (placebo 6.4%) sinusitis 9% (placebo 1.9%) NCT00488631 · Phase 3 100 mg colitis ulcerative 10.9% (placebo 18.6%) headache 9.6% (placebo 9%) nasopharyngitis 7.4% (placebo 6.4%) NCT00488631 · Phase 3 · monotherapy 100 mg colitis ulcerative 25% (placebo 18.6%) nasopharyngitis 14.3% (placebo 6.4%) arthralgia 10.7% (placebo 7.1%) NCT00488631 · Phase 3 50 mg colitis ulcerative 16.2% (placebo 18.6%) nasopharyngitis 9.1% (placebo 6.4%) headache 8.4% (placebo 9%) NCT00488631 · Phase 3 · combination 50 mg - 100 mg nasopharyngitis 16% (placebo 6.4%) pyrexia 16% (placebo 4.5%) upper respiratory tract infection 12% (placebo 2.6%) NCT00488631 · Phase 3 50 mg - 100 mg colitis ulcerative 10.5% (placebo 18.6%) dyspepsia 10.5% (placebo 1.3%) upper respiratory tract infection 10.5% (placebo 2.6%) NCT00488631 · Phase 3 50 mg colitis ulcerative 18.3% (placebo 18.6%) nasopharyngitis 10.8% (placebo 6.4%) arthralgia 9.7% (placebo 7.1%) NCT00488631 · Phase 3 50 mg abdominal pain 100% (placebo 2.6%) abdominal pain upper 100% (placebo 0.6%) bite 100% (placebo 0%) NCT00488631 · Phase 3 400 mg -> 200 mg headache 4.5% (placebo 5.2%) nausea 3.6% (placebo 1.8%) pyrexia 3% (placebo 2.1%) NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 200 mg -> 100 mg nasopharyngitis 3.9% (placebo 3.6%) headache 3.3% (placebo 5.2%) anaemia 2.4% (placebo 1.8%) NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 100 mg -> 50 mg headache 7% (placebo 5.2%) injection site erythema 4.2% (placebo 0%) anaemia 2.8% (placebo 1.8%) NCT00487539 · Phase 2/3 · combination · Ulcerative Colitis · phase 2/3 colitis ulcerative 10.5% NCT02318667 · Phase 4 · registry result, not featured evidence colitis ulcerative 13.7% nasopharyngitis 9.8% colitis 7.3% NCT02092285 · Phase 4 · registry result, not featured evidence anaemia 5.6% colitis ulcerative 5.6% headache 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · combination colitis ulcerative 11.1% anaemia 6.9% upper respiratory tract infection 5.6% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy colitis ulcerative 8.5% upper respiratory tract infection 8.5% headache 4.2% NCT03662542 · Phase 2 · registry result, not featured evidence · combination colitis ulcerative 7.5% anaemia 3% headache 3% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy anaemia 0% colitis ulcerative 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · combination colitis ulcerative 5.2% anaemia 0% headache 0% NCT03662542 · Phase 2 · registry result, not featured evidence · monotherapy |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cAssessment timepoints differ: 388 weeks versus 12 weeks.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation context differs: baseline_threshold differs (mayo<=12, mayo>=6 versus none recorded).
- fTreatment context has not been resolved for both arms.
- gAssessment timepoints differ: 52 weeks versus 54 weeks.
- hTrial phases differ: Phase 3 versus Phase 2/3.
- iPopulation context differs: prior_therapy differs (experienced versus naive).
- jTreatment context differs: monotherapy versus combination.
- kAssessment timepoints differ: 8 weeks versus 6 weeks.
- lTrial phases differ: Phase 3 versus Phase 4.
- mAssessment timepoints differ: 288 weeks versus 54 weeks.
- nThe assessment timepoint is not available for both results.
- oPopulation comparability has not been reviewed for 2 of these studies.
- pPopulation comparability has not been reviewed for 23 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 14 more results
show 2 more results
show 8 more results
show 2 more results
show 2 more results
+ 43 further endpoints in the CSV export.
golimumab
show 2 more results
show 1 more result
show 1 more result
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195702 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).
Next expected readout: December 2027 · NCT06440629 (registry estimate)
Reported efficacy
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 24; Change From Baseline in Modified Total Sharp X-ray Score at Week 52 (Baseline and Week 52); Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 52 (Baseline and Week 52): Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met. (met)
Result source: NCT00195702
golimumab · Simponi
Marketed by Johnson & Johnson
NCT00264537 · Phase 3 · completed
This trial was well designed -- randomized, fully blinded, and placebo-controlled with over 600 patients -- but its two main outcomes told different stories: the joint-damage (structural) outcome clearly favored golimumab plus methotrexate, while the joint-response (ACR50) outcome for the combined golimumab groups narrowly missed statistical significance against placebo, with only one of the individual dose comparisons reaching significance on its own. A well-designed trial with a split result on its co-primary outcomes does not qualify as strong evidence of benefit.
Reported efficacy
ACR20 response at week 14; change from baseline in HAQ score at week 24: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant. (met)
Result source: NCT00264550
Results for Rheumatoid Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | golimumab |
|---|---|---|
| ACR20 | 63.3% vs 29.5%+33.8 vs placeboNCT0019570228 other results
| 44.4% vs 33.1%+11.3 vs placeboNCT0026455025 other results
|
| ACR50 | 41.2% vs 45.9%vs MethotrexateNCT0019566319 other results
| 32.7% vs 29.4%+3.3 vs placeboNCT0026453719 other results
|
| ACR70 | 47.4% vs 22.7%+24.7 vs placeboNCT0087046716 other results
| 16.1% vs 25.9%vs GolimumabNCT01715896 |
| DAS28-CRP remission | 38.5% vs 42.9%vs Standard of CareNCT011624215 other results
| —Trial running · NCT03414502 |
| HAQ-DI, change | -0.6 vs -0.3−0.3 vs placeboNCT0019570222 other results
| 0.1 vs 0.1±0 vs placeboNCT002645508 other results
|
| Modified Sharp score, change | 0.1 vs 2.7−2.6 vs placeboNCT0019570215 other results
| 1.3 vs 1.4−0.1 vs placeboNCT0026453711 other results
|
ACR20
- adalimumab
- 63.3% vs 29.5%+33.8 vs placeboNCT00195702
28 other results
- 50.3% vs 33.9% NCT00647270
- 57% vs 35% NCT00538902
- 47.3% vs 33.9% NCT00647270
- 51.2% vs 35% NCT00538902
- 60.8% vs 29.5% NCT00195702
- 58.9% vs 24% NCT00195702
- 54.7% vs 24% NCT00195702
- 75.4% vs 56.4% NCT00870467
- 53.3% vs 61.5% NCT00195663
- 68.7% vs 61.5% NCT00195663
- 54.4% vs 62.6% NCT00195663
- 72.8% vs 62.6% NCT00195663
- 50% vs 59.9% NCT00195663
- 69% vs 59.9% NCT00195663
- 49.3% vs 56% NCT00195663
- 69.4% vs 56% NCT00195663
- 69.2% vs 71.4% NCT01500278
- 84.8% vs 80.4% NCT00420927
- 66.4% vs 80.4% NCT00420927
- 64.5% vs 60.8% NCT01500278
- 68% vs 68% NCT01712178
- 62% vs 68% NCT01712178
- 64.1% vs 37.1% NCT01162421
- 69.2% vs 57.1% NCT01162421
- 66.7% vs 60% NCT01162421
- 56.4% vs 68.6% NCT01162421
- 51.3% vs 65.7% NCT01162421
- 46.2% vs 65.7% NCT01162421
- golimumab
- 44.4% vs 33.1%+11.3 vs placeboNCT00264550
25 other results
- 36.5% vs 18% NCT00299546
- 40.9% vs 15.9% NCT01248780
- 34.7% vs 18% NCT00299546
- 58.5% vs 24.9% NCT00973479
- 56.2% vs 33.1% NCT00264550
- 55.1% vs 33.1% NCT00264550
- 51.6% vs 49.4% NCT00264537
- 35.3% vs 27.8% NCT00264550
- 42.6% vs 16% NCT00299546
- 42.4% vs 15.9% NCT01248780
- 31.3% vs 16% NCT00299546
- 48.1% vs 27.9% NCT00361335
- 39.8% vs 27.9% NCT00361335
- 61.6% vs 49.4% NCT00264537
- 61.6% vs 49.4% NCT00264537
- 61.6% vs 49.4% NCT00264537
- 59.6% vs 27.8% NCT00264550
- 59.6% vs 27.8% NCT00264550
- 51.6% vs 27.9% NCT00361335
- 55% vs 27.9% NCT00361335
- 55.9% vs 37.1% NCT00207714
- 79.4% vs 37.1% NCT00207714
- 60% vs 37.1% NCT00207714
- 50% vs 37.1% NCT00207714
- 62% vs 65.6% NCT01715896
ACR50
- adalimumab
- 41.2% vs 45.9%vs MethotrexateNCT00195663
19 other results
- 61.6% vs 45.9% NCT00195663
- 64.3% vs 38.7% NCT00870467
- 35% vs 40.5% NCT00195663
- 58.6% vs 40.5% NCT00195663
- 41.6% vs 44.4% NCT00195663
- 60.1% vs 44.4% NCT00195663
- 36.9% vs 42.8% NCT00195663
- 59% vs 42.8% NCT00195663
- 78.1% vs 69.6% NCT00420927
- 46.3% vs 69.6% NCT00420927
- 48% vs 50% NCT01712178
- 36% vs 40% NCT01712178
- 43.6% vs 22.9% NCT01162421
- 38.5% vs 22.9% NCT01162421
- 64.7% vs 51.6% NCT03823391
- 48.7% vs 40% NCT01162421
- 43.6% vs 34.3% NCT01162421
- 38.5% vs 45.7% NCT01162421
- 33.3% vs 42.9% NCT01162421
- golimumab
- 32.7% vs 29.4%+3.3 vs placeboNCT00264537
19 other results
- 19.4% vs 13.2% NCT00361335
- 12.5% vs 13.2% NCT00361335
- 36.5% vs 29.4% NCT00264537
- 40.3% vs 29.4% NCT00264537
- 21.1% vs 13.2% NCT00361335
- 21.7% vs 13.2% NCT00361335
- 38.4% vs 29.4% NCT00264537
- 18.2% vs 6.7% NCT00299546
- 15% vs 6.7% NCT00299546
- 34.9% vs 13.2% NCT00973479
- 28.9% vs 35.8% NCT00264537
- 11.6% vs 9.3% NCT00361335
- 8.6% vs 9.3% NCT00361335
- 44.6% vs 35.8% NCT00264537
- 44.2% vs 35.8% NCT00264537
- 25% vs 9.3% NCT00361335
- 18.6% vs 9.3% NCT00361335
- 44.4% vs 35.8% NCT00264537
- 34.8% vs 43.4% NCT01715896
ACR70
- adalimumab
- 47.4% vs 22.7%+24.7 vs placeboNCT00870467
16 other results
- 28.1% vs 28.4% NCT00195663
- 46.6% vs 28.4% NCT00195663
- 28.8% vs 29.2% NCT00195663
- 47.4% vs 29.2% NCT00195663
- 25.9% vs 27.2% NCT00195663
- 45.5% vs 27.2% NCT00195663
- 19.7% vs 22.2% NCT00195663
- 42.5% vs 22.2% NCT00195663
- 69.5% vs 57.1% NCT00420927
- 30.1% vs 57.1% NCT00420927
- 23.1% vs 40% NCT01162421
- 30.8% vs 20% NCT01162421
- 30.8% vs 14.3% NCT01162421
- 25.6% vs 22.9% NCT01162421
- 28.2% vs 8.6% NCT01162421
- 15.4% vs 2.9% NCT01162421
- golimumab
- 16.1% vs 25.9%vs GolimumabNCT01715896
DAS28-CRP remission
- adalimumab
- 38.5% vs 42.9%vs Standard of CareNCT01162421
5 other results
- 30.8% vs 34.3% NCT01162421
- 35.9% vs 22.9% NCT01162421
- 28.2% vs 31.4% NCT01162421
- 35.9% vs 11.4% NCT01162421
- 17.9% vs 8.6% NCT01162421
- golimumab
- —Trial running · NCT03414502
HAQ-DI, change
- adalimumab
- -0.6 vs -0.3−0.3 vs placeboNCT00195702
22 other results
- -0.6 vs -0.3 NCT00195702
- -0.6 vs -0.2 NCT00195702
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.3 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.5 vs -0.3 NCT00538902
- -0.4 vs -0.1 NCT00647270
- -0.4 vs -0.1 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.2 vs 0 NCT00647270
- -0.4 vs -0.3 NCT00538902
- -0.6 vs -0.2 NCT00195702
- -0.8 vs -0.8 NCT00195663
- -1.1 vs -0.8 NCT00195663
- -0.6 vs -0.7 NCT01500278
- -0.5 vs -0.3 NCT01162421
- -0.4 vs -0.4 NCT01162421
- -0.5 vs -0.5 NCT01162421
- -0.5 vs -0.6 NCT01162421
- -0.6 vs -0.6 NCT01162421
- -0.5 vs -0.6 NCT01162421
- golimumab
- 0.1 vs 0.1±0 vs placeboNCT00264550
8 other results
- 0.5 vs 0.1 NCT00264550
- 0.4 vs 0.1 NCT00264550
- 0.3 vs 0.1 NCT00264550
- -0.3 vs 0.2 NCT01248780
- 0.5 vs 0.1 NCT00973479
- 0.4 vs 0.1 NCT00264550
- 0.4 vs 0.1 NCT00264550
- -0.4 vs -0.6 NCT01715896
Modified Sharp score, change
- adalimumab
- 0.1 vs 2.7−2.6 vs placeboNCT00195702
15 other results
- 0.8 vs 2.7 NCT00195702
- 1.5 vs 2.4 NCT00870467
- 3 vs 5.7 NCT00195663
- 1.3 vs 5.7 NCT00195663
- 0.3 vs 1.3 NCT00195702
- 0.1 vs 4.8 NCT00195702
- 0.7 vs 6.2 NCT00195702
- 0.6 vs 1.3 NCT00195702
- 1.2 vs 4.8 NCT00195702
- 2.6 vs 6.2 NCT00195702
- 5.5 vs 10.4 NCT00195663
- 1.9 vs 10.4 NCT00195663
- 0.2 vs 1.6 NCT01162421
- 0.0 vs 0.9 NCT01162421
- 0.0 vs 2.2 NCT01162421
- golimumab
- 1.3 vs 1.4−0.1 vs placeboNCT00264537
11 other results
- 0.1 vs 1.4 NCT00264537
- 0.7 vs 1.4 NCT00264537
- 0.4 vs 1.4 NCT00264537
- 2.2 vs 2.2 NCT00264537
- 0 vs 0 NCT00264550
- 0.2 vs 2.2 NCT00264537
- 1.3 vs 2.2 NCT00264537
- 0.0 vs 1.1 NCT00973479
- 0.7 vs 2.2 NCT00264537
- 0 vs 0 NCT00264550
- 0 vs 0 NCT00264550
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. adalimumab: 13 of 13 rows · golimumab: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | golimumab Rows use multiple source trials |
|---|---|---|
| ACR20 responder rate · % of participants No placebo or comparator arm | 97% (n=133) @ 52wk*a,b,c NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 129 participants as posted show 1 more dose80% (n=5) @ 52wk* NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 4 participants as posted | 13.2% (n=91) @ 52wk50 mg SCa,b,c NCT01004432 · Phase 3 · combination show 1 more dose9.2% (n=184) @ 52wk2 mg/kg IV NCT01004432 · Phase 3 · combination |
| CDAI Clinical Remission responder rate · % of participants | 55.2% (n=105) vs 48.2% (n=112) placebo @ 78wk*a,d,b,c,e NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted show 1 more dose15.1% (n=259) vs 48.2% (n=112) placebo @ 78wk* NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted | 5.7% (n=70) vs 17.6% (n=68) Golimumab @ 24.14wk100 mgd,b,c,e NCT01715896 · Phase 2 · registry result, not featured evidence |
| DAS28-CRP absolute change · score | -2.6 vs -2.6 Standard of Care score @ 104wkd,b,c,f NCT01162421 · Phase 4 · registry result, not featured evidence | -2.11 vs -2.4 Golimumab score @ 24.14wk100 mgd,b,c,f NCT01715896 · Phase 2 · registry result, not featured evidence |
| DAS28-ESR absolute change · score No placebo or comparator arm | -3.7 score @ 52wka,b,c,g NCT00870467 · Phase 3 · registry result, not featured evidence show 1 more dose-1.9 score @ 52wk NCT00870467 · Phase 3 · registry result, not featured evidence | 0.209 score @ 76wk50 mg SCa,b,c,g NCT01004432 · Phase 3 · combination show 3 more doses-0.136 score @ 76wk50 mg SC NCT01004432 · Phase 3 · combination -0.013 score @ 76wk50 mg SC NCT01004432 · Phase 3 · combination -0.017 score @ 76wk2 mg/kg IV NCT01004432 · Phase 3 · combination |
| DAS28-ESR Remission responder rate · % of participants | 30.4% (n=171) vs 14.7% (n=163) placebo @ 26wk*h,b,c,i NCT00870467 · Phase 3 · registry result, not featured evidence · converted to % from 52 participants as posted | 17.3% (n=70) vs 19% (n=68) Golimumab @ 24.14wk100 mgh,b,c,i NCT01715896 · Phase 2 · registry result, not featured evidence |
| EULAR Good, Moderate responder rate · % of participants | 63% (n=64) vs 63% (n=64) AbbVie Adalimumab @ 24wkb,c,j NCT03172325 · Phase 3 · registry result, not featured evidence | 81.3% (n=395) vs 40.1% (n=197) placebo @ 14wk2 mg/kg + MTXb,c,j NCT00973479 · Phase 3 · registry result, not featured evidence · combination 4 other source trials69% (n=129) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 89 Participants as posted 62.5% (n=128) vs 44.2% (n=129) placebo @ 14wk*2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 80 Participants as posted 73.4% (n=128) vs 44.2% (n=129) placebo @ 14wk*4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination · converted to % from 94 Participants as posted 64.3% (n=129) vs 44.2% (n=129) placebo @ 14wk*4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted |
| HAQ-DI responder rate · % of participants | 41% (n=39) vs 57.1% (n=35) Standard of Care @ 104wkd,b,c,f NCT01162421 · Phase 4 · registry result, not featured evidence 2 other source trials48.2% (n=274) vs 53.3% (n=257) Methotrexate @ 104wk* NCT00195663 · Phase 3 · registry result, not featured evidence · converted to % from 132 participants as posted 63.8% (n=268) vs 53.3% (n=257) Methotrexate @ 104wk* NCT00195663 · Phase 3 · registry result, not featured evidence · combination · converted to % from 171 participants as posted | 58.7% (n=70) vs 69% (n=68) Golimumab @ 24.14wk100 mgd,b,c,f NCT01715896 · Phase 2 · registry result, not featured evidence |
| HAQ-DI absolute value · score | 0.25 vs 0.19 AbbVie Adalimumab score @ 24wkb,c NCT03172325 · Phase 3 · registry result, not featured evidence 1 other source trial1.01 vs 0.97 Adalimumab score @ 24wk40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence | 0.25 vs 0 placebo score @ 24wk100 mga,b,c NCT00299546 · Phase 3 · registry result, not featured evidence show 1 more dose0.125 vs 0 placebo score @ 24wk50 mg NCT00299546 · Phase 3 · registry result, not featured evidence |
| SDAI Remission responder rate · % of participants | 52.4% (n=105) vs 45.5% (n=112) placebo @ 78wk*a,d,b,c,e NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 55 Participants as posted show 1 more dose15.1% (n=259) vs 45.5% (n=112) placebo @ 78wk* NCT00420927 · Phase 4 · registry result, not featured evidence · combination · converted to % from 39 Participants as posted | 7.2% (n=70) vs 18.9% (n=68) Golimumab @ 24.14wk100 mgd,b,c,e NCT01715896 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 23.2%40 mg every other weekk NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 20.8%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 24.8%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 66.7% NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 32.5% NCT01162421 · Phase 4 · registry result, not featured evidence 10.3%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 12.3%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 9.2%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 6.1%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 7%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 15.3%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 39.4%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 26.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 36% NCT00690573 · Phase 3 · registry result, not featured evidence 9.4%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 62.1% NCT00195650 · Phase 3 · registry result, not featured evidence 5%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 8.2%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 11.2%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 47.6%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 4.1%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 2%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 9.1%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 64%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | 36.5%100 mg + placebok NCT00264537 · Phase 3 show 35 more results—100 mg SC NCT00264537 · Phase 3 —50 mg SC NCT00264537 · Phase 3 37.7%100 mg + methotrexate NCT00264537 · Phase 3 · combination 31.4%50 mg + methotrexate NCT00264537 · Phase 3 · combination 30.8%100 mg + placebo NCT00264550 · Phase 3 —100 mg SC injections NCT00264550 · Phase 3 —50 mg SC injections NCT00264550 · Phase 3 33.7%100 mg + MTX NCT00264550 · Phase 3 · combination 19.1%50 mg + MTX NCT00264550 · Phase 3 · combination —50mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —2mg/kg IV NCT01004432 · Phase 3 · combination —2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 17.5%2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 11.4%50 mg NCT01248780 · Phase 3 · registry result, not featured evidence · combination —100 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 56.2%100 mg NCT00299546 · Phase 3 · registry result, not featured evidence —50 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 60.1%50 mg NCT00299546 · Phase 3 · registry result, not featured evidence 8.3%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —2 mg/kg intravenous + 50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence · combination —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 15.7%100 mg NCT01715896 · Phase 2 · registry result, not featured evidence 23.5%100 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 14.7%100 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 20%50 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 29.4%50 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —40 mg every other weekk NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 —20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 —maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination —reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 1.3%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence —Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence — NCT02451748 · Phase 4 · registry result, not featured evidence · combination — NCT01500278 · Phase 4 · registry result, not featured evidence · combination 12.5% NCT01162421 · Phase 4 · registry result, not featured evidence 3.9%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 4.5%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination —ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 3.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 0%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 9.9%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 11.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination — NCT00690573 · Phase 3 · registry result, not featured evidence —DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 22.9% NCT00195650 · Phase 3 · registry result, not featured evidence 3%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence 4.4%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence —40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 11%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence 1.7%40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence —40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 0%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 2.3%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 2%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence —Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence —40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | 20.1%100 mg + placebok NCT00264537 · Phase 3 show 35 more results—100 mg SC NCT00264537 · Phase 3 —50 mg SC NCT00264537 · Phase 3 21.4%100 mg + methotrexate NCT00264537 · Phase 3 · combination 15.1%50 mg + methotrexate NCT00264537 · Phase 3 · combination 13.5%100 mg + placebo NCT00264550 · Phase 3 —100 mg SC injections NCT00264550 · Phase 3 —50 mg SC injections NCT00264550 · Phase 3 15.7%100 mg + MTX NCT00264550 · Phase 3 · combination 10.1%50 mg + MTX NCT00264550 · Phase 3 · combination —50mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —50 mg SC NCT01004432 · Phase 3 · combination —2mg/kg IV NCT01004432 · Phase 3 · combination —2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 8.1%2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 5.3%50 mg NCT01248780 · Phase 3 · registry result, not featured evidence · combination —100 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 17.6%100 mg NCT00299546 · Phase 3 · registry result, not featured evidence —50 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence 14.4%50 mg NCT00299546 · Phase 3 · registry result, not featured evidence 4.5%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence —2 mg/kg intravenous + 50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence · combination —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence —50 mg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination —100 mg NCT01715896 · Phase 2 · registry result, not featured evidence 8.8%100 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 2.9%100 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 5.7%50 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 11.8%50 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 13%40 mg every other weekk NCT00195702 · Phase 3 show 50 more results—40 mg every other week NCT00195702 · Phase 3 16%20 mg weekly NCT00195702 · Phase 3 —20 mg weekly, then 40 mg every other week NCT00195702 · Phase 3 7.4%maximum tolerated dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 4.5%reduced dose NCT03505008 · Phase 4 · registry result, not featured evidence · combination 2.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 7.7%40 mg Eow NCT02198651 · Phase 4 · registry result, not featured evidence 1%Adalimumab Tapering NCT02198651 · Phase 4 · registry result, not featured evidence 0% NCT02451748 · Phase 4 · registry result, not featured evidence · combination 13% NCT01500278 · Phase 4 · registry result, not featured evidence · combination 10.3% NCT01162421 · Phase 4 · registry result, not featured evidence 7.1%high dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 3.9%low dose NCT01185288 · Phase 4 · registry result, not featured evidence · combination 11.4%ADA+MTX/ADA+MTX (Arm 2) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 6.9%ADA+MTX/OL ADA+MTX (Arm 3) NCT00420927 · Phase 4 · registry result, not featured evidence · combination 2.9% NCT03172325 · Phase 3 · registry result, not featured evidence 7.1%20 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 3%10 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2%5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5.1%2.5 mg MTX NCT01185301 · Phase 3 · registry result, not featured evidence · combination 23.7%Adalimumab NCT00195663 · Phase 3 · registry result, not featured evidence 20.9%Adalimumab + Methotrexate NCT00195663 · Phase 3 · registry result, not featured evidence · combination 24% NCT00690573 · Phase 3 · registry result, not featured evidence 4.1%DB Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence —DB Adalimumab/RE OL Adalimumab NCT00870467 · Phase 3 · registry result, not featured evidence 51.1% NCT00195650 · Phase 3 · registry result, not featured evidence 1%40 mg/0.8 mL NCT01231321 · Phase 3 · registry result, not featured evidence —40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 4.9%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence 3.3%40 mg every other week NCT00647270 · Phase 3 · registry result, not featured evidence —80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 6.4%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 1.9%80 mg monthly NCT00647270 · Phase 3 · registry result, not featured evidence 22.7%40 mg or 80 mg every other week NCT00603993 · Phase 3 · registry result, not featured evidence 35.9%40 mg every other week NCT00235872 · Phase 3 · registry result, not featured evidence —40 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 0%40 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —80 mg NCT00538902 · Phase 2/3 · registry result, not featured evidence 2.5%80 mg EOW NCT00538902 · Phase 2/3 · registry result, not featured evidence —Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%Period 1: Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 12.5%Period 2: Adalimumab / Adalimumab NCT03823391 · Phase 2 · registry result, not featured evidence 0%40 mg NCT02565810 · Phase 2 · registry result, not featured evidence 2.3%Current Formulation for 24 Weeks, NCT01752855 · Phase 2 · registry result, not featured evidence 4.5%New Formulation for 48 Weeks NCT01752855 · Phase 2 · registry result, not featured evidence 0%40 mg every other week NCT01712178 · Phase 2 · registry result, not featured evidence 0%Current Formulation Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 0%New Formulation of Adalimumab NCT01561313 · Phase 2 · registry result, not featured evidence 40%40 mg Eow NCT00235833 · Phase 2 · registry result, not featured evidence | —100 mg + placebok NCT00264537 · Phase 3 show 35 more results38.7%100 mg SC NCT00264537 · Phase 3 32%50 mg SC NCT00264537 · Phase 3 —100 mg + methotrexate NCT00264537 · Phase 3 · combination —50 mg + methotrexate NCT00264537 · Phase 3 · combination —100 mg + placebo NCT00264550 · Phase 3 45.7%100 mg SC injections NCT00264550 · Phase 3 31.4%50 mg SC injections NCT00264550 · Phase 3 —100 mg + MTX NCT00264550 · Phase 3 · combination —50 mg + MTX NCT00264550 · Phase 3 · combination 4.4%50mg SC NCT01004432 · Phase 3 · combination 2.7%50 mg SC NCT01004432 · Phase 3 · combination 4.6%50 mg SC NCT01004432 · Phase 3 · combination 4.7%50 mg SC NCT01004432 · Phase 3 · combination 5.4%2mg/kg IV NCT01004432 · Phase 3 · combination 19.7%2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination —2 mg/kg + MTX NCT00973479 · Phase 3 · registry result, not featured evidence · combination 6.1%50 mg NCT01248780 · Phase 3 · registry result, not featured evidence · combination 33.3%100 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence —100 mg NCT00299546 · Phase 3 · registry result, not featured evidence 34.7%50 mg SC injections NCT00299546 · Phase 3 · registry result, not featured evidence —50 mg NCT00299546 · Phase 3 · registry result, not featured evidence 6%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence 2.7%50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence 6.9%2 mg/kg intravenous + 50 mg subcutaneous NCT00975130 · Phase 3 · registry result, not featured evidence · combination 6.8%50 mg NCT00361335 · Phase 3 · registry result, not featured evidence 6.3%4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence 13.3%2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence 9.1%50 mg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 14%4 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 13.7%2 mg/kg NCT00361335 · Phase 3 · registry result, not featured evidence · combination 2.9%100 mg NCT01715896 · Phase 2 · registry result, not featured evidence 15.2%100 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 14.3%100 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 18.9%50 mg every 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence 15.6%50 mg every 2 or 4 weeks NCT00207714 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 40 mg every other weekk injection site pain 17.9% (placebo 21.5%) upper respiratory tract infection 16.9% (placebo 11%) headache 11.6% (placebo 5%) NCT00195702 · Phase 3 show 40 more results20 mg weekly injection site pain 17.5% (placebo 21.5%) upper respiratory tract infection 16.5% (placebo 11%) headache 13.2% (placebo 5%) NCT00195702 · Phase 3 maximum tolerated dose liver function test abnormal 8.8% abdominal pain upper 2.9% dry mouth 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination reduced dose dry mouth 3% alanine aminotransferase increased 1.5% cough 1.5% NCT03505008 · Phase 4 · registry result, not featured evidence · combination 40 mg Eow cough 2.7% (placebo 5%) nasopharyngitis 2.7% (placebo 20%) urinary tract infection 1.4% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence 40 mg Eow nasopharyngitis 10.3% (placebo 20%) upper respiratory tract infection 7.7% (placebo 0%) hepatic enzyme increased 5.1% (placebo 0%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.7% (placebo 20%) arthralgia 5.9% (placebo 0%) influenza 4.9% (placebo 10%) NCT02198651 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.3% headache 10.7% upper respiratory tract infection 10.3% NCT01500278 · Phase 4 · registry result, not featured evidence · combination rheumatoid arthritis 25.6% nasopharyngitis 20.5% alanine aminotransferase increased 15.4% NCT01162421 · Phase 4 · registry result, not featured evidence high dose nausea 10.3% upper respiratory tract infection 7.7% urinary tract infection 7.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination low dose nausea 9.7% fatigue 9.1% upper respiratory tract infection 9.1% NCT01185288 · Phase 4 · registry result, not featured evidence · combination cough 6.7% (placebo 3.6%) influenza 5.7% (placebo 2.7%) nasopharyngitis 5.7% (placebo 3.6%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 11.2% (placebo 6.3%) nasopharyngitis 8.9% (placebo 3.6%) alanine aminotransferase increased 6.2% (placebo 2.7%) NCT00420927 · Phase 4 · registry result, not featured evidence · combination injection site reaction 8.8% headache 5.9% nausea 5.9% NCT03172325 · Phase 3 · registry result, not featured evidence 20 mg MTX nasopharyngitis 11.2% headache 9.2% alopecia 8.2% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 10 mg MTX nausea 13.1% alopecia 6.1% diarrhoea 6.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 5 mg MTX diarrhoea 6% headache 6% nasopharyngitis 6% NCT01185301 · Phase 3 · registry result, not featured evidence · combination 2.5 mg MTX nausea 7.1% arthralgia 6.1% abdominal pain upper 4.1% NCT01185301 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 22.6% headache 21.5% nausea 17.5% NCT00195663 · Phase 3 · registry result, not featured evidence nasopharyngitis 30.2% headache 20.5% upper respiratory tract infection 18.7% NCT00195663 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 56% upper respiratory tract infection 56% influenza 32% NCT00690573 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.2% (placebo 16.6%) hepatic function abnormal 8.2% (placebo 5.5%) alanine aminotransferase increased 7.6% (placebo 3.7%) NCT00870467 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 46.3% rheumatoid arthritis 25.4% sinusitis 24.9% NCT00195650 · Phase 3 · registry result, not featured evidence 40 mg/0.8 mL nasopharyngitis 4% respiratory disorder 4% headache 3% NCT01231321 · Phase 3 · registry result, not featured evidence 40 mg every other week nausea 5.5% (placebo 5.3%) headache 4.9% (placebo 5.3%) nasopharyngitis 4.9% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 6.6% (placebo 5.3%) upper respiratory tract infection 2.6% (placebo 7%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly upper respiratory tract infection 3.2% (placebo 7%) nasopharyngitis 2.7% (placebo 5.3%) cough 0% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 80 mg monthly nausea 6.2% (placebo 5.3%) upper respiratory tract infection 5.2% (placebo 7%) headache 4.7% (placebo 5.3%) NCT00647270 · Phase 3 · registry result, not featured evidence 40 mg or 80 mg every other week nasopharyngitis 60.2% adverse drug reaction 29.5% antinuclear antibody positive 15.9% NCT00603993 · Phase 3 · registry result, not featured evidence 40 mg every other week nasopharyngitis 45% adverse drug reaction 23.6% dna antibody positive 16.2% NCT00235872 · Phase 3 · registry result, not featured evidence 40 mg EOW upper respiratory tract infection 14% (placebo 11.7%) injection site pruritus 5.8% (placebo 0%) nasopharyngitis 5.8% (placebo 6.7%) NCT00538902 · Phase 2/3 · registry result, not featured evidence 80 mg EOW upper respiratory tract infection 12.4% (placebo 11.7%) nasopharyngitis 7.4% (placebo 6.7%) injection site pruritus 4.1% (placebo 0%) NCT00538902 · Phase 2/3 · registry result, not featured evidence urinary tract infection 11.8% abdominal discomfort 5.9% arthralgia 5.9% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 12.5% bronchitis 6.3% drug hypersensitivity 6.3% NCT03823391 · Phase 2 · registry result, not featured evidence nasopharyngitis 15.9% rheumatoid arthritis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence nasopharyngitis 13.6% cystitis 9.1% upper respiratory tract infection 9.1% NCT01752855 · Phase 2 · registry result, not featured evidence 40 mg every other week nasopharyngitis 10% cystitis 8% nausea 8% NCT01712178 · Phase 2 · registry result, not featured evidence pharyngitis 1.6% rash erythematous 1.6% protein urine present 0% NCT01561313 · Phase 2 · registry result, not featured evidence protein urine present 1.6% pharyngitis 0% rash erythematous 0% NCT01561313 · Phase 2 · registry result, not featured evidence 40 mg Eow nasopharyngitis 60% diarrhoea 24% pruritus 20% NCT00235833 · Phase 2 · registry result, not featured evidence | show 26 more results50 mg SC upper respiratory tract infection 26.2% alanine aminotransferase increased 18% bronchitis 15.1% NCT00264537 · Phase 3 100 mg SC injections upper respiratory tract infection 34.8% cough 19% nasopharyngitis 19% NCT00264550 · Phase 3 50 mg SC injections upper respiratory tract infection 37.1% cough 22.9% bronchitis 17.1% NCT00264550 · Phase 3 50 mg SC upper respiratory tract infection 9.3% depression 5.3% sinusitis 5.3% NCT01004432 · Phase 3 · combination 50 mg SC upper respiratory tract infection 6.7% headache 5.5% urinary tract infection 5.5% NCT01004432 · Phase 3 · combination 50 mg SC upper respiratory tract infection 6.1% urinary tract infection 6.1% sinusitis 5.7% NCT01004432 · Phase 3 · combination 2mg/kg IV upper respiratory tract infection 8.2% sinusitis 7.1% bronchitis 6% NCT01004432 · Phase 3 · combination 2 mg/kg + MTX upper respiratory tract infection 13.7% bronchitis 9.4% rheumatoid arthritis 8.4% NCT00973479 · Phase 3 · registry result, not featured evidence · combination 50 mg upper respiratory tract infection 19.1% liver function test abnormal 6.1% anaemia 1.5% NCT01248780 · Phase 3 · registry result, not featured evidence · combination 100 mg SC injections upper respiratory tract infection 31.2% nasopharyngitis 18.8% rheumatoid arthritis 16.7% NCT00299546 · Phase 3 · registry result, not featured evidence 50 mg SC injections upper respiratory tract infection 25.5% sinusitis 19.4% headache 14.3% NCT00299546 · Phase 3 · registry result, not featured evidence 50 mg subcutaneous nasopharyngitis 0% upper respiratory tract infection 0% NCT00975130 · Phase 3 · registry result, not featured evidence 50 mg subcutaneous nasopharyngitis 7.1% upper respiratory tract infection 2.4% NCT00975130 · Phase 3 · registry result, not featured evidence 2 mg/kg intravenous + 50 mg subcutaneous upper respiratory tract infection 6.1% nasopharyngitis 5.3% NCT00975130 · Phase 3 · registry result, not featured evidence · combination 50 mg upper respiratory tract infection 8.5% (placebo 9.3%) nasopharyngitis 7.7% (placebo 5.4%) rheumatoid arthritis 5.1% (placebo 4.7%) NCT00361335 · Phase 3 · registry result, not featured evidence 4 mg/kg upper respiratory tract infection 12.6% (placebo 9.3%) rheumatoid arthritis 9.4% (placebo 4.7%) bronchitis 6.3% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence 2 mg/kg rheumatoid arthritis 15.6% (placebo 4.7%) upper respiratory tract infection 10.9% (placebo 9.3%) bronchitis 7.8% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence 50 mg upper respiratory tract infection 7.2% (placebo 9.3%) rheumatoid arthritis 6.9% (placebo 4.7%) bronchitis 5.3% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence · combination 4 mg/kg upper respiratory tract infection 12.2% (placebo 9.3%) nausea 10.7% (placebo 7%) bronchitis 7.7% (placebo 5.4%) NCT00361335 · Phase 3 · registry result, not featured evidence · combination 2 mg/kg upper respiratory tract infection 12.1% (placebo 9.3%) nausea 11% (placebo 7%) headache 9.3% (placebo 10.1%) NCT00361335 · Phase 3 · registry result, not featured evidence · combination 100 mg nasopharyngitis 5.7% headache 4.3% hepatic enzyme increased 4.3% NCT01715896 · Phase 2 · registry result, not featured evidence 100 mg every 4 weeks headache 27.3% (placebo 20.6%) nausea 21.2% (placebo 5.9%) upper respiratory tract infection 15.2% (placebo 20.6%) NCT00207714 · Phase 2 · registry result, not featured evidence 100 mg every 2 or 4 weeks injection site erythema 28.6% (placebo 11.8%) nasopharyngitis 22.9% (placebo 8.8%) nausea 22.9% (placebo 5.9%) NCT00207714 · Phase 2 · registry result, not featured evidence 50 mg every 4 weeks headache 21.6% (placebo 20.6%) nasopharyngitis 21.6% (placebo 8.8%) rheumatoid arthritis 21.6% (placebo 14.7%) NCT00207714 · Phase 2 · registry result, not featured evidence 50 mg every 2 or 4 weeks nausea 25% (placebo 5.9%) rheumatoid arthritis 21.9% (placebo 14.7%) headache 18.8% (placebo 20.6%) NCT00207714 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dTrial phases differ: Phase 4 versus Phase 2.
- eAssessment timepoints differ: 78 weeks versus 24.14 weeks.
- fAssessment timepoints differ: 104 weeks versus 24.14 weeks.
- gAssessment timepoints differ: 52 weeks versus 76 weeks.
- hTrial phases differ: Phase 3 versus Phase 2.
- iAssessment timepoints differ: 26 weeks versus 24.14 weeks.
- jAssessment timepoints differ: 24 weeks versus 14 weeks.
- kPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 1 more result
show 1 more result
show 7 more results
show 15 more results
show 11 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 4 more results
+ 222 further endpoints in the CSV export.
golimumab
show 4 more results
show 6 more results
show 3 more results
show 1 more result
show 1 more result
+ 24 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · golimumab's landscape